Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02019940 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02019940 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 18 participants.
The verdict
NCT02019940, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This open label study will evaluate the safety and efficacy of riluzole in patients with PTSD. Patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient, with a one month follow up at week 16.
Interventions
- DRUG Riluzole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2014-01 |
| Est. Completion | 2020-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02019940
The ClinicalTrials.gov registry entry for NCT02019940 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Riluzole is the first listed.
NCT02019940 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02019940 about?
NCT02019940 is a clinical study titled "A Pilot Study Of Riluzole In Patients With Post Traumatic Stress Disorder (PTSD)". This open label study will evaluate the safety and efficacy of riluzole in patients with PTSD. Patients will receive riluzole 50mg twice per day orally for 12 weeks as outpatient, with a one month follow up at week 16.
What is the current status of trial NCT02019940?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2014-01. Estimated completion is 2020-01.
What interventions are being tested in trial NCT02019940?
The interventions under investigation include: Riluzole (DRUG).
Who is sponsoring clinical trial NCT02019940?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.